Beta-Amyloid Peptide/a2-Macroglobulin Interactions

About the Research Project
Program
Award Type
Standard
Award Amount
$199,523
Active Dates
April 01, 1999 - March 31, 2001
Grant ID
A1999011
Summary
It has been suggested that the protein a2-macroglobulin (a2M) could be an inhibitor of beta-amyloid (Ab) aggregation. The goal of this study is to elucidate the nature of the interaction between a2M and the Ab peptide. Dr. Gonias will accomplish this by first identifying the site in a2M which binds to Ab. Because a2M also has important interactions with various growth factors and cytokines that have been implicated in Alzheimer’s disease, Dr. Gonias will also attempt to determine if a2M-Ab interaction alters a2M binding to cytokines. One possible outcome of these studies is the identification of novel peptides that have the ability to alter Ab fibril formation — an activity with potential therapeutic value for Alzheimer’s disease.
Related Grants
Alzheimer's Disease Research
Understanding the Choroid Plexus in Alzheimer’s Disease
Active Dates
July 01, 2025 - June 30, 2028

Principal Investigator
Monica Santisteban, PhD
Current Organization
Vanderbilt University Medical Center
Alzheimer's Disease Research
Changes in Cerebral Blood Flow and Dementia
Active Dates
July 01, 2025 - June 30, 2028

Principal Investigator
Daniel Bos, MD, PhD
Current Organization
Erasmus University Medical Center
Alzheimer's Disease Research
The Role of the Brain Vascular-Immune Processes in Alzheimer’s
Active Dates
July 01, 2024 - June 30, 2026

Principal Investigator
Julie Ottoy, PhD
Current Organization
Sunnybrook Research Institute